Pliant Therapeutics initiated with an Overweight at JPMorgan
The Fly

Pliant Therapeutics initiated with an Overweight at JPMorgan

JPMorgan analyst Eric Joseph initiated coverage of Pliant Therapeutics with an Overweight rating and $42 price target. The company’s approach could add efficacy on to the standard of care in idiopathic pulmonary fibrosis without worsening the safety and tolerability profile, Joseph tells investors in a research note. The analyst believes current Pliant share levels "imply rather conservative success assumptions." He sees data readouts in the first half of 2023 incrementally de-risking bextograst in the "multibillion" IPF market."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on PLRX:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App